Dupilumab and Alopecia Areata

Some providers have used dupilumab off-label for the treatment of recalcitrant alopecia areata, particularly in patients with atopic dermatitis. However, many clinicians have noted mixed results, with some patients reporting improvement while other patients experiencing new-onset or worsening alopecia areata. The purpose of this systematic review was to investigate the clinical characteristics and outcomes in cases of dupilumab-treated and dupilumab-induced alopecia areata.部分医疗提供者已超说明书（off-label）使用度普利尤单抗（dupilumab）治疗顽固性斑秃（recalcitrant alopecia areata），尤其针对合并特应性皮炎（atopic dermatitis）的患者。然而，许多临床医生观察到的疗效结果不一——部分患者报告症状改善，而另一些患者则出现斑秃新发或加重的情况。本系统综述旨在探讨度普利尤单抗治疗相关及诱导相关斑秃病例的临床特征与转归。

搜集汇总

背景与挑战

背景概述

该数据集是一个系统性综述研究，聚焦于使用药物dupilumab治疗或诱导的斑秃的临床特征和结果，旨在分析其疗效差异。数据集包含补充图和表格文件，适用于皮肤病学和药物研究领域，遵循CC BY 4.0许可协议。